scispace - formally typeset
Journal ArticleDOI

A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis.

TLDR
It is suggested that metronidazole may be useful in the maintenance of remission in patients with ulcerative colitis, but that it is ineffective in the therapy of the acute attack.
Abstract
In a double-blind, randomized trial, we tested the effectiveness of metronidazole (0.6 g/day) against sulfasalazine (2 g/day) in the maintenance of remission in patients with ulcerative colitis. The patients were in remission for 1-11 months at entry to trial, which lasted for 12 months. Forty patients entered the trial and 33 completed it. Metronidazole was found to be slightly more effective than sulfasalazine, a difference statistically significant only at 12 months. Six patients also completed a crossover trial. Remission was maintained for 12 months in 3 patients by metronidazole and in none of the 6 by sulfasalazine. No significant side effects were noted, and in particular, no paresthesias were reported. This trial, as well as our previous one, suggests that metronidazole may be useful in the maintenance of remission in patients with ulcerative colitis, but that it is ineffective in the therapy of the acute attack.

read more

Citations
More filters
Journal ArticleDOI

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

TL;DR: The most widely used index for severe UC remains that of Truelove and Witts3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia (> 90 bpm), or temperature > 37.8 °C, or anaemia (haemoglobin 30 mm/h) has severe ulcerative colitis (Table 1.3) as mentioned in this paper.
Journal ArticleDOI

Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis

TL;DR: The colon mucus in animal models that spontaneously develop colitis and in patients with active UC allows bacteria to penetrate and reach the epithelium, and this suggests a novel model of UC pathophysiology.
Journal ArticleDOI

European evidence-based Consensus on the management of ulcerative colitis: Current management.

TL;DR: The most widely used index for severe UC is Truelove and Wi_tts as discussed by the authors, which is defined as any patient who has a bloody stool frequency ≥ 6/day and a tachycardia (> 90 bpm), or temperature > 37.8 °C, or anaemia (haemoglobin 30 mm/h) has severe ulcerative colitis.

European-evidence-based consensus on the management of ulcerative colitis: Current management (vol 2, pg 24, 2008)

TL;DR: The simplest, best validated and most widely used index for identifying acute severe UC remains that of Truelove & Wi_tts 3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia and temperature > 37.8 °C, or anaemia has severe ulcerative colitis.
Related Papers (5)